These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36036094)

  • 1. An allopurinol adherence tool using plasma oxypurinol concentrations.
    Smith-Diaz N; Stocker SL; Stamp LK; Dalbeth N; Phipps-Green AJ; Merriman TR; Wright DFB
    Br J Clin Pharmacol; 2023 Jul; 89(7):1956-1964. PubMed ID: 36036094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
    Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
    Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualising the dose of allopurinol in patients with gout.
    Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
    Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
    Toprover M; Crittenden DB; Modjinou DV; Oh C; Krasnokutsky S; Fisher MC; Keenan RT; Pillinger MH
    Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):87-91. PubMed ID: 31140959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
    Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
    Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
    Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
    Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: in vitro and in vivo.
    Wang X; Nie SF; Li W; Luan L; Pan W
    Drug Dev Ind Pharm; 2007 Sep; 33(9):1024-9. PubMed ID: 17891589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
    Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Hishe HZ; Stocker SL; Stamp LK; Dalbeth N; Merriman TR; Phipps-Green A; Wright DFB
    Clin Transl Sci; 2023 Mar; 16(3):422-428. PubMed ID: 36398357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing adherence to allopurinol for gout: patients' perspectives.
    Spragg JCJ; Michael TJF; Aslani P; Coleshill MJ; Chan JS; Day RO; Stocker SL
    Br J Clin Pharmacol; 2023 Jul; 89(7):1978-1991. PubMed ID: 36607199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
    Chao J; Terkeltaub R
    Curr Rheumatol Rep; 2009 Apr; 11(2):135-40. PubMed ID: 19296886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopurinol and kidney function: An update.
    Stamp LK; Chapman PT; Palmer SC
    Joint Bone Spine; 2016 Jan; 83(1):19-24. PubMed ID: 26453097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
    Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
    Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
    Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
    Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
    Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
    Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.